The future leaves
signals in time.

As the ESMO conference begins, Tango's pancreatic cancer combination therapy is showing striking promise. Additionally, detailed data regarding Moderna and Merck's cancer vaccine has been released early.

A bespoke vaccine tailored to target an individual's unique skin cancer reduced rates of recurrence or death in a late-stage trial, making approval expected next year, according to the report. The finding is based on trial-stage evidence.

A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity. A clinical trial reported a 52% reduction in symptoms and 68% remission, and researchers believe the technology could transform PTSD care.

Tango Therapeutics reported that an experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer in a trial of the combo therapy. The figure is as reported by the company.

A seven-year study found that people with Parkinson's disease who were more physically active experienced slower declines in memory, thinking, and movement abilities; those exercising more than eight hours per week showed almost no average cognitive decline. The findings suggest staying active may offer important benefits as the disease progresses.

According to ScienceDaily, researchers have uncovered a hidden immune defense capable of attacking small cell lung cancer, an aggressive disease that often escapes conventional treatments. The specialized immune cells can recognize and destroy cancer cells even when tumors disguise themselves from the immune system; further details on stage were not provided.

According to Nature, a Moderna mRNA vaccine was reported to nearly halve the risk of skin cancer returning. The item provides no further details on trial stage, study population, or other specifics.

Nature Medicine publishes an article outlining ten strategic priorities for research and public health concerning the human microbiome and chronic disease. The available context does not specify the priorities or their authors.

Nature Medicine carries the randomized phase 2 AMPLIFY-7P trial, which evaluates a lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer. The supplied context contains no results, so no efficacy or safety conclusions can be drawn.

New results indicate that the Moderna-Merck mRNA cancer vaccine helps prevent cancer recurrence and death.

Moderna and Merck have released top-line results saying their mRNA cancer vaccine cut death and recurrence by 42%. The companies had previously reported that the trial succeeded.

According to STAT, detailed data confirm that a personalized mRNA cancer vaccine from Moderna and Merck met key endpoints in a melanoma trial. The companies reported the vaccine reduced the risk of disease recurrence in melanoma patients by 42% compared with standard treatment.

According to STAT, AbbVie's experimental therapy lutikizumab, intended for a chronic skin condition, succeeded in a late-stage trial, but the results missed market expectations.

A US-backed vaccine trial involving babies was canceled following international outcry. According to the report, the decried trial was canceled last week, after police seized vaccine doses.

The data reveal for the Moderna-Merck cancer vaccine is approaching, and STAT+ provides information regarding what to expect from this event.

A two-year clinical trial found that fish oil supplements delivered omega-3s to the brain but did not improve memory or protect against Alzheimer's-related brain shrinkage. Researchers suspect obtaining these nutrients through a healthy diet may offer benefits supplements alone cannot provide.

Oxford scientists captured virus-like particles assembling step by step, showing how a simple trial-and-error process builds complex structures with remarkable precision. They identified a molecular turning point that speeds assembly, which could suggest new ways to disrupt viruses and develop vaccines.